| |
N (%)
|
Sum of squares
|
df
|
Mean Square
|
F
|
p value
|
|---|
|
SPAG5
|
Clinical stage
|
Stage I
|
12(30)
|
102.71
|
2
|
51.35
|
4.50
|
.018
|
|
Stage II
|
19(47.5)
|
|
Stages III and IV
|
9(22.5)
|
|
Molecular stage
|
Stage I
|
30(75)
|
2.74
|
2
|
1.37
|
.09
|
.90
|
|
Stage II
|
5(12.5)
|
|
Stages III and IV
|
5(12.5)
|
|
Molecular subtypes
|
Luminal A
|
12(30)
|
34.11
|
3
|
11.37
|
.83
|
.48
|
|
Luminal B
|
22(55)
|
|
HER2 positive
|
2(5)
|
|
Basal-like
|
4(10)
|
|
NuMA
|
Clinical stage
|
Stage I
|
12(30)
|
4.03
|
2
|
2.02
|
.32
|
.72
|
|
Stage II
|
19(47.5)
|
|
Stages III and IV
|
9(22.5)
|
|
Molecular stage
|
Stage I
|
30(75)
|
8.73
|
2
|
4.36
|
.72
|
.49
|
|
Stage II
|
5(12.5)
|
|
Stages III and IV
|
5(12.5)
|
|
Molecular subtypes
|
Luminal A
|
12(30)
|
44.97
|
3
|
14.99
|
2.88
|
.049
|
|
Luminal B
|
22(55)
|
|
HER2 positive
|
2(5)
|
|
Basal-like
|
4(10)
|
- One-way ANOVA was employed to analyze the difference between SPAG5 and NuMA gene expression levels related to clinical stage, molecular stage and molecular subtypes. Normal variable distribution and equality of variances were checked by Kolmogorov-Smirnov and Levene’s test, respectively. Our chosen significance level was 0.05
- N number, df degree of freedom, SPAG5 sperm-associated antigen, NuMA nuclear mitotic apparatus protein
